Aclarion Inc (ACON) 뉴스

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aclarion Announces First Commercial Agreement in Michigan

Sheridan Community Hospital is the First Healthcare Institution in Michigan With Nociscan Agreement Expands Nociscan Access to John Keller, MD, a...

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Vitality is a top 4 Provider of Private Medical Insurance in the UK.Aclarion now has Payer Coverage From 3 of the 4 Largest Private Health...

Form 253G3 -

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have...

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to...

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being...

Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared...

Aclarion Announces Closing of $3.0 Million Public Offering

BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a...

Form 8-K - Current report